The SOLO1 study evaluated olaparib in patients with somatic and germline BRCAm (7), and the PRIMA / ENGOT-Ov26 study evaluated niraparib in patients with newly diagnosed advanced ovarian cancer (not restricted to BRCAm carriers [4]).